BioTrove, Inc. Appoints Gregory C. Critchfield, M.D. to Board of Directors
Seventh corporate director is president of leading pharmacogenetics company
Woburn, MA, April 3, 2007 – BioTrove, Inc. today named Gregory C. Critchfield, M.D., M.S., to its board of directors, adding his expertise in disease testing and pharmaceutical development to the BioTrove board. Dr. Critchfield, current president of Myriad Genetic Laboratories, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), expands the BioTrove board to seven corporate directors.
“Greg strongly complements our board,” said Albert A. Luderer, Ph.D., president and CEO, BioTrove. “He is a leading expert in the development and commercialization of medical tests and pharmaceutical therapies based on genetics. Greg’s history of striving to improve public health through genomics and new pharmaceuticals is completely in synch with BioTrove’s mission.”
Dr. Critchfield is currently President of Myriad Genetic Laboratories, Inc., a position he has held since July 1998. Previously, he was Senior Vice President, Chief Medical and Scientific Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). He is a sought-after consultant, working with various national government, university, and healthcare organizations to improve disease testing for the public. Dr. Critchfield has served as a reviewer and study section chair for numerous SBIR, R01 and STTR grant applications in biomedical computing for the National Institutes of Health (NIH). He has also been a reviewer for the Clinical Chemistry journal.
“We welcome Greg to BioTrove,” said Robert H. Ellis, executive chairman, BioTrove. “Greg’s overall wealth of experience in the biopharmaceutical arena will bring new insights into our commercialization and R&D programs.”
Dr. Critchfield received his M.D. from the University of Utah and his M.S. in Biophysical Sciences from the University of Minnesota. He is Board Certified in Clinical Pathology.
About Myriad Genetics, Inc.
Myriad is a biopharmaceutical company focused on the development of novel healthcare products. In addition to an expanding preclinical pipeline, Myriad’s drug discovery and development is strong in the areas of Alzheimer’s disease, cancer and antivirals. Myriad also develops and markets molecular-diagnostic medicine products. For more information, visit www.myriad.com.
About BioTrove, Inc.
BioTrove, Inc. offers two innovative technology platforms: RapidFire™, which enables the acceleration of drug discovery and pipeline decisions, and OpenArray™, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health. With more than half of the world’s ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove’s products and services ensure that an industry committed to accuracy and speed can meet business goals.
RapidFire™ Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.
The OpenArray™ Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray™ system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.
For more information, please visit www.biotrove.com or contact:
Dr. Albert Luderer,
President and CEO
Makovsky + Company